BIOCHEMICAL DERANGEMENTS RELATED TO METABOLIC SYNDROME IN EPILEPTIC PATIENTS ON TREATMENT WITH VALPROIC ACID

Valproate (VPA), a branched chain fatty acid, is a broad spectrum anticonvulsant used for the treatment of epilepsy such as generalized and partial seizures [1]. Continuous administration of antiepileptic drugs results in long standing complications such as psychiatric disorders, metabolic disorder, endocrine disorders, idiosyncratic reactions and drug interaction effects in some cases [2]. Valproate is metabolized in the liver by glucuronidation process and to a lesser extent by β oxidation. [3].

Seguir leyendo →
0

The Quality of Life of the Elderly with Epilepsy: A Systematic Review

The life expectancy of the population has increased due to improvements in medicine, public health, nutrition, income, education, and migration [1]. Between 2015 and 2030, “The number of people in the world aged 60 and over is expected to grow by 56%, from 901 million to 1.4 billion” [2]. Consequently, long-term care and age-related chronic illness increases in addition to treatment of disease, resulting in longer life expectancy. The quality of a persons’ life has been shown to be of ...

Seguir leyendo →
0

Functional network changes in the hippocampus contribute to depressive symptoms in epilepsy

Depression is highly common in patients with epilepsy, with a prevalence of approximately 30% in patients with recurrent seizures [1]. Depression not only negatively affects patient quality of life but is also correlated with cognitive functioning in patients with epilepsy [2,3]. However, the mechanisms underlying the comorbidity of epilepsy and depression remain unclear. Evidence from clinical and laboratory research indicates that there are common pathogenic mechanisms associated with epilepsy and depression [4].

Seguir leyendo →
0
Página 4 de 51 «...23456...»